Bezuclastinib Plus Sunitinib Halves Risk of Progression in Second-Line GIST - Targeted Oncology

Bezuclastinib Plus Sunitinib Halves Risk of Progression in Second-Line GIST    Targeted Oncology Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST    Yahoo Finance Cogent Biosciences Reports PEAK Phase 3 Trial Results Demonstrating Significant PFS Improvement with Bezuclastinib Combination in GIST Patients    Quiver Quantitative Bezuclastinib Plus Sunitinib Cuts Risk of Progression or Death in Half vs Sunitinib Alone in Advanced GIST    OncLive FDA Accepts NDA, Grants Priority Review to Bezuclastinib/Sunitinib in Pretreated GIST    CancerNetwork

Original source: Google News